Cargando…

Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells

A receptor–ligand interaction exclusive to natural killer (NK) cell–mediated recognition and triggering of tumor cell destruction has not yet been identified. In contrast, molecules that are involved in cellular adhesion and regulation of NK cytolysis have been well studied. In this report, a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Ballabh, Mondragon, Mary O., Tao, Shi-Zhen, Norin, Allen J.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2196309/
https://www.ncbi.nlm.nih.gov/pubmed/9151698
_version_ 1782148036536827904
author Das, Ballabh
Mondragon, Mary O.
Tao, Shi-Zhen
Norin, Allen J.
author_facet Das, Ballabh
Mondragon, Mary O.
Tao, Shi-Zhen
Norin, Allen J.
author_sort Das, Ballabh
collection PubMed
description A receptor–ligand interaction exclusive to natural killer (NK) cell–mediated recognition and triggering of tumor cell destruction has not yet been identified. In contrast, molecules that are involved in cellular adhesion and regulation of NK cytolysis have been well studied. In this report, a novel tumor surface protein is identified that exhibits characteristics of a recognition structure for naive NK cells. A tagged ligand–cell adsorption technique revealed a 38.5-kD plasma membrane protein (p38.5) from a prototypical NK-susceptible cell line (K562) that preferentially bound to NK cells (CD3(−)CD5(−)CD16(+)) relative to T lymphocytes (CD3(+)CD5(+) CD16(−)). The molecule was purified to apparent homogeneity for further characterization. An amino acid sequence of an 11-mer internal peptide of p38.5 did not exhibit homology to known proteins. Affinity-purified antibody generated against this peptide (anti-p38.5) reacted with a single protein of 38.5 kD on Western blots of whole cell extracts of K562. Flow cytometry and immunoprecipitation studies of surface-labeled tumor cells demonstrated expression of p38.5 on NK-susceptible tumor cell lines (K562, MOLT-4, Jurkat), whereas p38.5 was not detected on NK-resistant tumor cell lines (A549, Raji, MDA-MB-231). Significantly, p38.5 loss variants derived from wild-type Jurkat and Molt-4 cell lines exhibited decreased susceptibility to NK cell–mediated lysis demonstrating a strong association between cell surface expression of p38.5 and cytotoxicity. Purified p38.5 retained preferential binding to NK cells and inhibited NK activity in a dose-dependent manner, thereby providing direct evidence of a role in the lytic process. Binding studies identified a 70-kD membrane protein from NK cells as a possible receptor for the p38.5 tumor ligand. Consistent with cellular adsorption studies, the 70-kD, p38.5 binding protein was not detected on T lymphocytes. Based on studies demonstrating selective binding of p38.5 to NK cells, lack of expression on NK-resistant tumor cell lines and ability of the purified molecule to block cytolysis, we conclude that p38.5 may serve as a recognition/triggering ligand for naive human NK cells.
format Text
id pubmed-2196309
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21963092008-04-16 Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells Das, Ballabh Mondragon, Mary O. Tao, Shi-Zhen Norin, Allen J. J Exp Med Article A receptor–ligand interaction exclusive to natural killer (NK) cell–mediated recognition and triggering of tumor cell destruction has not yet been identified. In contrast, molecules that are involved in cellular adhesion and regulation of NK cytolysis have been well studied. In this report, a novel tumor surface protein is identified that exhibits characteristics of a recognition structure for naive NK cells. A tagged ligand–cell adsorption technique revealed a 38.5-kD plasma membrane protein (p38.5) from a prototypical NK-susceptible cell line (K562) that preferentially bound to NK cells (CD3(−)CD5(−)CD16(+)) relative to T lymphocytes (CD3(+)CD5(+) CD16(−)). The molecule was purified to apparent homogeneity for further characterization. An amino acid sequence of an 11-mer internal peptide of p38.5 did not exhibit homology to known proteins. Affinity-purified antibody generated against this peptide (anti-p38.5) reacted with a single protein of 38.5 kD on Western blots of whole cell extracts of K562. Flow cytometry and immunoprecipitation studies of surface-labeled tumor cells demonstrated expression of p38.5 on NK-susceptible tumor cell lines (K562, MOLT-4, Jurkat), whereas p38.5 was not detected on NK-resistant tumor cell lines (A549, Raji, MDA-MB-231). Significantly, p38.5 loss variants derived from wild-type Jurkat and Molt-4 cell lines exhibited decreased susceptibility to NK cell–mediated lysis demonstrating a strong association between cell surface expression of p38.5 and cytotoxicity. Purified p38.5 retained preferential binding to NK cells and inhibited NK activity in a dose-dependent manner, thereby providing direct evidence of a role in the lytic process. Binding studies identified a 70-kD membrane protein from NK cells as a possible receptor for the p38.5 tumor ligand. Consistent with cellular adsorption studies, the 70-kD, p38.5 binding protein was not detected on T lymphocytes. Based on studies demonstrating selective binding of p38.5 to NK cells, lack of expression on NK-resistant tumor cell lines and ability of the purified molecule to block cytolysis, we conclude that p38.5 may serve as a recognition/triggering ligand for naive human NK cells. The Rockefeller University Press 1997-05-19 /pmc/articles/PMC2196309/ /pubmed/9151698 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Das, Ballabh
Mondragon, Mary O.
Tao, Shi-Zhen
Norin, Allen J.
Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells
title Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells
title_full Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells
title_fullStr Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells
title_full_unstemmed Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells
title_short Preferential Interaction of a Novel Tumor Surface Protein (p38.5) with Naive Natural Killer Cells
title_sort preferential interaction of a novel tumor surface protein (p38.5) with naive natural killer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2196309/
https://www.ncbi.nlm.nih.gov/pubmed/9151698
work_keys_str_mv AT dasballabh preferentialinteractionofanoveltumorsurfaceproteinp385withnaivenaturalkillercells
AT mondragonmaryo preferentialinteractionofanoveltumorsurfaceproteinp385withnaivenaturalkillercells
AT taoshizhen preferentialinteractionofanoveltumorsurfaceproteinp385withnaivenaturalkillercells
AT norinallenj preferentialinteractionofanoveltumorsurfaceproteinp385withnaivenaturalkillercells